• Sulfaphenazole Restores Tissue Perfusion After Ischemic Inju

  2026-05-09

  This study demonstrates that Sulfaphenazole, a potent CYP2C9 inhibitor, rapidly restores tissue perfusion and reduces the severity of both pressure and thermal skin injuries in a murine model. These findings provide mechanistic insights into the modulation of vascular dysfunction via cytochrome P450 2C inhibition, supporting Sulfaphenazole's translational potential in tissue repair.

• Mdivi-1 and ECM-Mitochondria Crosstalk: A New Era in Transla

  2026-05-08

  This thought-leadership article explores the emerging paradigm of extracellular matrix (ECM)–mitochondria communication and its implications for mitochondrial dynamics research, apoptosis modulation, and neuroprotection. We integrate the latest mechanistic insights with practical guidance for translational researchers, highlighting the strategic role of Mdivi-1—a selective DRP1 inhibitor from APExBIO—in advancing experimental rigor and innovation across cell-based and in vivo platforms.

• ETS1 Regulates Mitophagy via SENP2/HSPA8/FUNDC1 in Bronchopu

  2026-05-08

  This study uncovers how ETS1 acts as a transcriptional regulator to inhibit mitochondrial damage-induced autophagy in bronchopulmonary dysplasia (BPD) by targeting the SENP2/HSPA8/FUNDC1 axis. The findings provide mechanistic insight into mitophagy control in lung injury and offer a foundation for targeted research on autophagy modulation in developmental lung diseases.

• L-NAME Hydrochloride: Advanced NOS Inhibition for Vascular S

  2026-05-07

  L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) delivers precise, reproducible nitric oxide synthase inhibition for dissecting vascular tone and inflammation signaling in both cellular and animal models. This article provides actionable workflows, troubleshooting strategies, and an evidence-backed translation of recent supramolecular anti-inflammatory research to maximize insight from your cardiovascular disease models.

• tFUS Attenuates Stroke Neuroinflammation via Nespas/miR-383-

  2026-05-07

  This study identifies transcranial focused ultrasound stimulation (tFUS) as a potent neuromodulatory tool that reduces NLRP3-driven neuroinflammation after ischemic stroke by modulating the Nespas/miR-383-3p/SHP2 signaling pathway. The findings clarify the mechanistic role of SHP2 in post-stroke microglial activation and provide a molecular basis for precision targeting in neuroinflammatory disease models.

• Toremifene vs Tamoxifen: Systematic Evidence for Advanced Br

  2026-05-06

  A Cochrane systematic review rigorously compared Toremifene and Tamoxifen, two oral selective estrogen receptor modulators, in the treatment of advanced breast cancer. The meta-analysis found no significant differences in efficacy or survival, but highlighted nuanced differences in adverse effect profiles, providing critical insights for hormone receptor modulation strategies.

• Toremifene Citrate: Precision Tools for Dissecting Estrogen

  2026-05-06

  Explore Toremifene Citrate as an advanced oral selective estrogen receptor modulator for research. This article uniquely focuses on protocol optimization and the impact of pharmacogenomics on assay design, offering insights beyond standard product overviews.

• E-64d: Precision Cysteine Protease Inhibition in Cell Death

  2026-05-05

  E-64d enables highly selective, cell-permeant inhibition of calpain and cathepsins, facilitating mechanistic dissection of lysoptosis and regulated cell death in both in vitro and in vivo models. This guide details experimental workflows, advanced use-cases, and troubleshooting strategies to help researchers harness the full translational power of E-64d from APExBIO.

• Angiotensin III (human, mouse): Bridging RAAS and Viral Rese

  2026-05-05

  Explore the multifaceted role of Angiotensin III in cardiovascular and emerging virology research. This in-depth analysis reveals how this key RAAS peptide informs assay design and bridges domains beyond standard cardiovascular paradigms.

• D-Lin-MC3-DMA: Optimizing Ionizable Cationic Liposomes for m

  2026-05-04

  Explore the advanced science behind D-Lin-MC3-DMA as an ionizable cationic liposome, delving into its mechanistic strengths and the machine-learning-driven future of RNA therapeutics. Discover unique insights that guide practical assay design and unlock next-generation delivery potential.

• Synthetic Efferocytic Microglia for Amyloid-β Clearance in A

  2026-05-04

  Shao et al. present a synthetic efferocytic receptor (SER) engineered for microglia, enabling selective, anti-inflammatory clearance of amyloid-β in Alzheimer's disease (AD) mouse models. Their lipid nanoparticle mRNA delivery strategy circumvents proinflammatory side-effects typical of antibody therapies, offering a promising platform for targeted CNS immunomodulation.

• Toremifene vs Tamoxifen in Advanced Breast Cancer: Evidence

  2026-05-03

  A Cochrane systematic review compared the efficacy and safety of toremifene and tamoxifen—two oral selective estrogen receptor modulators—in the treatment of advanced breast cancer. The analysis found no significant differences in major clinical outcomes, supporting toremifene as a viable alternative for hormone receptor modulation in this setting.

• Recombinant Human Growth Hormone: Protocols, Insights & Inno

  2026-05-02

  Unlock the full potential of Recombinant Human Growth Hormone (GH, somatotropin) in advanced cell proliferation and signaling studies. This guide delivers actionable experimental workflows, troubleshooting strategies, and leverages new mechanistic insights to optimize your research with APExBIO’s validated somatotropin reagent.

• PR-619: Technical Guidance for Deubiquitylating Enzyme Inhib

  2026-05-01

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for broad-spectrum modulation of ubiquitination pathways in cell-based assays. It is best suited for workflows dissecting DUB function, autophagy activation, and disease models where proteasome activity must remain intact. It is not appropriate for scenarios requiring selective DUB targeting or long-term solution storage.

• Tacalcitol Monohydrate Enhances 5-FU Efficacy in Colorectal

  2026-05-01

  This article examines how tacalcitol monohydrate, a synthetic analog of vitamin D3, enhances the anticancer activity of 5-fluorouracil (5-FU) in colorectal cancer (CRC) cells by downregulating thymidylate synthase. The findings offer mechanistic insights and practical considerations for researchers seeking to improve CRC therapeutic strategies using vitamin D receptor agonists.

15308 records 1/1021 page Next 12345 下5页 Last page